<- Go Home
Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Market Cap
$11.4M
Volume
16.5K
Cash and Equivalents
$2.6M
EBITDA
-$1.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.2K
52 Week Low
$0.55
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.01
Price / Tangible Book Value
0.01
Enterprise Value
$8.8M
Enterprise Value / EBITDA
-7.47
Operating Income
-$1.3M
Return on Equity
57.83%
Return on Assets
-26.65
Cash and Short Term Investments
$2.6M
Debt
N/A
Equity
$5.3M
Revenue
N/A
Unlevered FCF
-$771.8K
Sector
Biotechnology
Category
N/A